OncologyTube Professional - Patients Click Here
22,139 video views
Loading........
Description: Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer are best served by receiving the best agents up front, a strategy that implies a ...
09:08
Dr. Jack West describes an emerging theme that the best outcomes for patients with lung cancer and likely other cancer are best served by receiving the best agents up front, a strategy that implies a value in integrating more treatments into early combos.
by:BeaconMedIC | 105 views
15:36
Dr. Jack West reviews general principles for how local therapies are increasingly appropriate for selected patients with advanced NSCLC, whether at initial management, for limited progression on systemic therapy, or as local consolidation therapy.
by:BeaconMedIC | 100 views
03:39
Dr. Dan Goldstein reviews results of a trial of chemo regimen TIP (paclitaxel, ifosfamide, cisplatin) vs BEP (bleomycin, etoposide, cisplatin) for intermediate/po​or risk germ cell tumors, with discussion of outcomes in patients with a p53 mutation.
by:BeaconMedIC | 77 views
01:34
Dr. Daniel Goldstein summarizes findings of a trial presented at ASCO 2018 by Dr. Kellolumpu-Leht​inen, assessing the benefit of adjuvant docetaxel for patients after radiation for patients with high or intermediate risk localized prostate cancer.
by:BeaconMedIC | 73 views
02:46
Dr. Daniel Goldstein reviews data on the positive predictive value of PET PSMA imaging in patients with biochemically relapsed prostate cancer, as presented by Wolfgang Fendler & colleagues at ASCO 2018.
by:BeaconMedIC | 65 views
03:02
Dr. Daniel Goldstein considers new data by Clarke & colleagues on a combination of the PARP inhibitor olaparib with abiraterone for molecularly unselected metastatic prostate cancer, along with providing a context of results from similar prior research.
by:BeaconMedIC | 68 views
02:02
Dr. Daniel Goldstein reviews data by Drs. Gulley & colleagues on PROSTVAC vaccine in metastatic prostate cancer & discusses the implications of trials that fail in phase III despite looking extremely favorable in phase II studies.
by:BeaconMedIC | 39 views
01:08
Dr. Daniel Goldstein reviews data in genitourinary oncology from ASCO 2018, including a study of higher dose or prolonged duration of radium-223 (Xofigo) compared to standard dosing for 6 months with this agent in patients with metastatic prostate cancer.
by:BeaconMedIC | 21 views
02:17
Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a place as treatment for a subset of these patients.
by:BeaconMedIC | 56 views
02:18
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reporte​d quality of life on atezolizumab/be​vacizumab compared to sunitinib in metastatic kidney cancer, along with the context of other treatment options in this setting.
by:BeaconMedIC | 16 views

About BeaconMedIC
Description: Dr. Jack West reviews emerging new information and controversial topics in health care in general, cancer treatment in particular.

Company: Beacon Medical Interchange is a venture founded in 2016 by Dr. Jack West to facilitate communication of medical experts with industry leaders on the evolution of medical care trends in general and cancer management in particular. Focusing on issues ranging from behavioral economics and decision-making based on emerging data to trends such as telemedicine, social media, and the growing role of algorithm-based interventions, Dr. West facilitates data collection and moderates interactive meetings, advisory boards, producing summary reports of current and projected market analysis.
Links
Channel Url:

Website:


Other Links:


Social Links: